Logo

SISI

Shineco, Inc.

SISI

Shineco, Inc. • NASDAQ
$0.36 ▲ 0.00% (+0.00)
Market Cap $326923
52w High $271.50
52w Low $0.17
Dividend Yield 0%
P/E 0
Volume 1.07K
Outstanding Shares 900.62K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $40.971K ▼ $3.747M ▲ $-15.119M ▼ -36.901K% ▼ $-48.17 ▼ $-3.363M ▼
Q2-2025 $3.049M ▲ $2.76M ▲ $-1.624M ▲ -53.272% ▲ $-45.21 ▲ $-990.275K ▼
Q1-2025 $2.174M ▼ $2.682M ▼ $-2.023M ▲ -93.035% ▲ $-117.22 ▲ $-973.846K ▲
Q4-2024 $4.498M ▲ $5.505M ▲ $-20.139M ▼ -447.763% ▼ $-3.031K ▼ $-18.738M ▼
Q3-2024 $1.349M $1.174M $-3.349M -248.176% $-600.37 $12.599M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $192.735K ▼ $85.503M ▼ $59.442M ▲ $18.165M ▼
Q2-2025 $731.79K ▲ $95.797M ▲ $53.302M ▲ $33.111M ▼
Q1-2025 $288.714K ▼ $93.814M ▲ $50.484M ▲ $33.281M ▲
Q4-2024 $366.14K ▼ $84.179M ▼ $47.602M ▼ $26.001M ▼
Q3-2024 $565.483K $101.867M $54.984M $36.171M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $2.641M ▲ $-430.341K ▲ $-212.836K ▼ $189.624K ▼ $-459.732K ▼ $5.68M ▲
Q2-2025 $-1.624M ▲ $-604.643K ▲ $361.542K ▲ $739.711K ▼ $488.148K ▲ $-604.608K ▲
Q1-2025 $-2.558M ▲ $-2.085M ▼ $-3.133M ▲ $5.066M ▼ $-136.322K ▲ $-2.101M ▼
Q4-2024 $-20.27M ▼ $-868.231K ▼ $-7.04M ▼ $7.819M ▲ $-170.447K ▲ $-1.083M ▼
Q3-2024 $-3.349M $-351.143K $-23.315K $-233.52K $-621.717K $-351.91K

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
Other Agricultural Products
Other Agricultural Products
 $0 ▲$10.00M ▲$0 ▼$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Shineco’s income statement shows a company still in the “promise” stage rather than the “results” stage. Revenue over the past few years has been essentially negligible, with only a very small uptick recently. The core picture is recurring operating losses and no clear sign yet that the new biotech strategy has begun to translate into meaningful sales. Reported earnings per share look extremely volatile, but that is driven largely by repeated reverse stock splits rather than real swings in business performance. Overall, this is an early‑stage, loss‑making profile where the commercial engine is not yet built.

Balance Sheet

Balance Sheet The balance sheet is very small and quite thin. Total assets are modest, cash has been drawn down compared with a few years ago, and there is now some debt where there previously was essentially none. Equity is positive but not large, which means there is limited buffer to absorb further losses. In simple terms, the company does not have a lot of financial cushion, and its ability to withstand setbacks without new funding appears constrained.

Cash Flow

Cash Flow Cash flow mirrors the income statement: operations are not generating cash, and the business has been consuming a small but persistent amount of cash each year. There is almost no spending on physical assets, which fits an R&D‑heavy biotech model, but it also means growth is mainly about people, labs, and partnerships rather than owned facilities. Because there is little or no internally generated cash, the company likely depends on external capital raises or borrowing to keep funding its strategy.

Competitive Edge

Competitive Edge Competitively, Shineco is trying to reposition itself from an agriculture/textile background into high‑tech biotech and digital health. It is aiming at attractive but very crowded areas: stem cells, extracellular vesicles, advanced diagnostics, and blockchain‑based asset management. The company highlights proprietary extraction technology, a unique angle on tokenizing cell assets, and regional partnerships as differentiators. However, its market presence and brand in biotech are still emerging, revenue is minimal, and much larger and better‑funded players operate in each of these fields. At this stage, its competitive position looks more like an early‑stage challenger with interesting ideas than an established contender with a proven moat.

Innovation and R&D

Innovation and R&D Innovation is clearly the heart of the Shineco story. The company is investing its efforts into stem cell platforms, extracellular vesicle therapies, a specialized phospholipid extraction process, and a blockchain platform for biological asset management. It also has a notable tangible product in its rapid cardiac diagnostic test, which already has regulatory approval in China. On paper, these are cutting‑edge and differentiated projects, supported by collaborations in Southeast Asia and with blockchain partners. The main gaps are limited visibility into detailed pipelines, timelines, and clinical data. Execution risk is high: moving from technology concepts to approved, widely used medical products is a long, uncertain, and capital‑intensive path.

Summary

Putting it all together, Shineco is a very small, financially fragile company attempting a major strategic pivot into advanced biotech and digital health. The financial statements show minimal revenue, ongoing losses, and a thin balance sheet with little room for error, alongside repeated reverse stock splits that signal pressure to maintain its listing. Against that, the company presents an ambitious innovation story across stem cells, extracellular vesicles, novel extraction technology, diagnostics, and blockchain‑based asset tokenization. The long‑term opportunity is almost entirely based on future execution rather than current financial performance. Uncertainty is high on both the scientific and commercial fronts, and the key things to watch going forward are evidence of real product adoption, clearer clinical progress, and a more sustainable financial base.

NEWS

September 12, 2025 · 9:30 AM UTC

Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

Read more

September 10, 2025 · 9:30 AM UTC

Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

Read more